Results 61 to 70 of about 1,312 (178)

Basic Dermatology [PDF]

, 2014
ДЕРМАТОЛОГИ
Adaskevich, V. P., Katsina, M. A., Tsikhanouskaya, I. V.   +2 more
core  

Ofloxacin/ornidazole induced fixed drug eruptions: a case report [PDF]

, 2016
The term fixed drug eruption describes the development of one or more annular or oval erythematous patches as a result of systemic exposure to a drug; these reactions normally resolve with hyperpigmentation and may recur at the same site with reexposure ...
Manchukonda, Ravi Shankar, Ramakrishna, Manjushree   +1 more
core   +2 more sources

Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment

Clinical and Translational Science, Volume 18, Issue 12, December 2025.
ABSTRACT Breast cancer is among the most common cancers in U.S. women. Epidermal growth factor receptor inhibitors (EGFRIs) target pathways driving tumor growth but frequently cause dermatologic toxicities that impact quality of life and treatment adherence.
Tvisha Devireddy, Clara Lim, Jhillika Patel, Isabella J. Tan, Bernard A. Cohen   +4 more
wiley   +1 more source

Toxic epidermal necrolysis and Stevens-Johnson syndrome

Orphanet Journal of Rare Diseases, 2010
Toxic epidermal necrolysis (TEN) and Stevens Johnson Syndrome (SJS) are severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes.
French Lars E, Harr Thomas
doaj   +1 more source

World Association for Veterinary Dermatology Consensus Statement for Diagnosis, and Evidence‐Based Clinical Practice Guidelines for Treatment and Prevention of Canine Leishmaniosis

Veterinary Dermatology, Volume 36, Issue 6, Page 723-787, December 2025.
Hyperkeratosis of (a) the footpads and (b) the nasal planum. ABSTRACT Background Canine leishmaniosis (CanL) due to Leishmania infantum remains common, and veterinarians do not always follow scientifically sound approaches for diagnosis, treatment and prevention. Objectives To provide consensus guidelines for diagnosis and evidence‐based guidelines for
Manolis N. Saridomichelakis, Gad Baneth, Silvia Colombo, Filipe Dantas‐Torres, Lluís Ferrer, Alessandra Fondati, Guadalupe Miró, Laura Ordeix, Domenico Otranto, Chiara Noli   +9 more
wiley   +1 more source

Rare delayed hypersensitivity reactions to contrast media:Severe cutaneous adverse reactions [PDF]

The risk of developing a severe delayed cutaneous reaction (SCAR) is very low following iodine-based contrast medium (ICM) administration and extremely low following gadolinium-based contrast agent (GBCA) administration.
Dekkers, Ilona A., Laguna, José J., van de Ven, Annick A.J.M., van der Molen, Aart J., Vega, Francisco   +4 more
core   +1 more source

Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: A systematic review [PDF]

, 2012
Glatiramer acetate and interferon-beta are approved first-line disease-modifying treatments (DMTs) for multiple sclerosis (MS). DMTs can be associated with cutaneous adverse events, which may influence treatment adherence and patient quality of life.
Alava C, Batista J, Bayerl C, Debat Zoguereh D, Devonshire V, Dimov V, Gaudez C, Heinzerling L, Kaiser C, Madray M, Nakamura Y, Navne JE, Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years, Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis, Poulin F, Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis, Rio J, Sanchez-Lopez J, Weinberg JM, Yang CH, Ziegler VR   +20 more
core   +1 more source

Fixed drug eruption – A retrospective review of 146 patients in a tertiary hospital in Southern Taiwan

Dermatologica Sinica
In this retrospective study, the clinical characteristics of 146 patients diagnosed with fixed drug eruption (FDE) in a tertiary hospital in Southern Taiwan were analyzed.
Jui-Wen Yeh, Wei-Ting Liu
doaj   +1 more source

A fixed dose combination of ofloxacin and ornidazole induced fixed drug eruptions [PDF]

, 2018
Fixed drug eruptions (FDEs) may account for 16-21% of all cutaneous drug eruptions. Recent research suggests a cell-mediated process that initiates both the active and quiescent lesions.
Manchukonda, Ravi Shankar, Thippeswamy, Chandrakantha   +1 more
core   +2 more sources

Skin tests in the diagnosis of adverse drug reactions: a systematic review [PDF]

, 2020
Adverse Drug Reactions (ADRs) are common and influence negatively the patient's therapeutic options. They recognize multiple pathogenic mechanisms, some of immunological origin, and the clinical manifestations involve several organs and systems ...
Bianchi, Leonardo, Corazza, Monica, Fabbrocini, Gabriella, Foti, Caterina, Hansel, Katharina, Micali, Giuseppe, Napolitano, Maddalena, Patruno, Cataldo, Pigatto, Paolo D, Romita, Paolo, Stingeni, Luca, Tramontana, Marta   +11 more
core   +1 more source